EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

Salvage-line of Capecitabine Plus Oxaliplatin Therapy (XELOX) for Patients With Inoperable/Advanced Gastric Cancer Resistant/Intolerant to Cisplatin (OGSG1403)

Naotoshi Sugimoto, Junji Kawada, Yoshio Oka, Shugo Ueda, Kohei Murakami, Kazuhiro Nishikawa, Yukinori Kurokawa, Kazumasa Fujitani, Hisato Kawakami, Shunji Endo, Daisuke Sakai, Toshio Shimokawa und 1 weitere

Anticancer Research · 2025

DOI: 10.21873/anticanres.17418 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Anticancer Research, 2025. Verfasst von Naotoshi Sugimoto und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan; na2-sugimoto@oici.jp. Hauptthemen laut MEDLINE: Stomach Neoplasms, Capecitabine, Salvage Therapy, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsCapecitabineSalvage TherapyAntineoplastic Combined Chemotherapy ProtocolsDrug Resistance, NeoplasmCisplatinOxaloacetatesHumansMaleMiddle AgedFemaleAgedDeoxycytidineFluorouracilOxaliplatinAdultProspective StudiesProgression-Free Survival

Stichwörter der Autor:innen

Cancer chemotherapy agentsgastric cancerplatinum cross-resistantprogression-free survivalsalvage therapy

Substanzen

CapecitabineCisplatinOxaloacetatesDeoxycytidineFluorouracilOxaliplatin

Autor:innen und Institutionen

  • Department of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan; na2-sugimoto@oici.jp.
  • Department of Surgery, Kaizuka City Hospital, Kaizuka, Japan.
  • Department of Surgery, Minoh City Hospital, Minoh, Japan.
  • Department of Gastroenterological Surgery, Kitano Hospital, Osaka, Japan.
  • Department of Surgery, Nagahama City Hospital, Nagahama, Japan.
  • Department of Surgery, Kansai Rosai Hospital, Amagasaki, Japan.

Zitieren

APA

Sugimoto, N., Kawada, J., Oka, Y., Ueda, S., Murakami, K., Nishikawa, K., Kurokawa, Y., Fujitani, K., Kawakami, H., Endo, S., Sakai, D., Shimokawa, T., & Satoh, T. (2025). Salvage-line of Capecitabine Plus Oxaliplatin Therapy (XELOX) for Patients With Inoperable/Advanced Gastric Cancer Resistant/Intolerant to Cisplatin (OGSG1403). Anticancer Research. https://doi.org/10.21873/anticanres.17418

Vancouver

Sugimoto N, Kawada J, Oka Y, Ueda S, Murakami K, Nishikawa K, et al. Salvage-line of Capecitabine Plus Oxaliplatin Therapy (XELOX) for Patients With Inoperable/Advanced Gastric Cancer Resistant/Intolerant to Cisplatin (OGSG1403). Anticancer Research. 2025. doi:10.21873/anticanres.17418

BibTeX
@article{Sugimoto2025,
  author = {Sugimoto, Naotoshi and Kawada, Junji and Oka, Yoshio and Ueda, Shugo and Murakami, Kohei and Nishikawa, Kazuhiro and Kurokawa, Yukinori and Fujitani, Kazumasa and Kawakami, Hisato and Endo, Shunji and Sakai, Daisuke and Shimokawa, Toshio and Satoh, Taroh},
  title = {Salvage-line of Capecitabine Plus Oxaliplatin Therapy (XELOX) for Patients With Inoperable/Advanced Gastric Cancer Resistant/Intolerant to Cisplatin (OGSG1403)},
  journal = {Anticancer Research},
  year = {2025},
  doi = {10.21873/anticanres.17418}
}
Kostenlos starten →